Khadija Saeed

Eli Lilly shares climbed Thursday after Repertoire Immune Medicines announced a partnership with the drugmaker worth up to $1.93 billion, including an $85 million upfront payment, plus milestone and royalty fees. Lilly was up 0.5% at $1,028.89 in late morning trading, while the S&P 500 slipped about 1.4%. Repertoire will lead early research using its Decode platform, which explores how T cells attack diseased cells, before Lilly takes the programs to the clinic and eventually the market.